Blockade of the Ubiquitin Protease UBP43 Destabilizes Transcription Factor PML/RARα and Inhibits the Growth of Acute Promyelocytic Leukemia

Yongli Guo1, Andrey V. Dolinko6, Fadzai Chinyengere1, Bruce Stanton3, Jennifer M. Bomberger3, Eugene Demidenko4,5, Da-Cheng Zhou6, Robert Gallagher7, Tian Ma1, Fabrizio Galimberti1, Xi Liu1, David Sekula1, Sarah Freemantle1, and Ethan Dmitrovsky1,2,5

**Abstract**

More effective treatments for acute promyelocytic leukemia (APL) are needed. APL cell treatment with all-trans-retinoic acid (RA) degrades the chimeric, dominant-negative–acting transcription factor promyelocytic leukemia gene (PML)/RARα, which is generated in APL by chromosomal translocation. The E1-like ubiquitin-activating enzyme (UBE1L) associates with interferon-stimulated gene ISG15 that binds and represses PML/RARα protein. Ubiquitin protease UBP43/USP18 removes ISG15 from conjugated proteins. In this study, we explored how RA regulates UBP43 expression and the effects of UBP43 on PML/RARα stability and APL growth, apoptosis, or differentiation. RA treatment induced UBE1L, ISG15, and UBP43 expression in RA-sensitive but not RA-resistant APL cells. Similar in vivo findings were obtained in a transgenic mouse model of transplantable APL, and in the RA response of leukemic cells harvested directly from APL patients. UBP43 knockdown repressed PML/RARα protein levels and inhibited RA-sensitive or RA-resistant cell growth by destabilizing the PML domain of PML/RARα. This inhibitory effect promoted apoptosis but did not affect the RA differentiation response in these APL cells. In contrast, elevation of UBP43 expression stabilized PML/RARα protein and inhibited apoptosis. Taken together, our findings define the ubiquitin protease UBP43 as a novel candidate drug target for APL treatment. Cancer Res; 70(23); 1

**Introduction**

Acute promyelocytic leukemia (APL) is a distinct subset of myeloid leukemia (FAB, M3) (1). The t(15;17) rearrangement present in APL fuses the promyelocytic leukemia gene (PML) on chromosome 15 with the retinoic acid receptor α (RARα) on chromosome 17 (2, 3). PML/RARα is a dominant-negative translocation product etiologic for APL (2, 3). Engineered PML/RARα transgenic mice spontaneously develop leukemia, as reviewed (4, 5). All-trans-retinoic acid (RA) successfully treated APL patients by triggering leukemic cell differentiation (6). One retinoid mechanism activated is inhibited apoptosis. Taken together, our findings define the ubiquitin protease UBP43 as a novel candidate drug target for APL treatment. Cancer Res; 70(23); 1

**Authors’ Affiliations:** Departments of 1Pharmacology and Toxicology, 2Medicine, 3Physiology, and 4Community and Family Medicine, and the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire; 5Dartmouth College, Hanover, New Hampshire; and 7Department of Medicine and Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York

**Note:** Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

**Corresponding Author:** Ethan Dmitrovsky, Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755. Phone: 603-650-1707; Fax: 603-650-1129; E-mail: ethan.dmitrovsky@dartmouth.edu.

**doi:** 10.1158/0008-5472.CAN-10-1100

©2010 American Association for Cancer Research.
RA-mediated differentiation of APL cells is accompanied by PML/RARα proteolysis through caspase- and proteasome-dependent degradation pathways, as previously summarized (4, 5, 24). Loss of PML/RARα expression and induction of apoptosis in APL cells followed arsenic treatment (25) or transfection of ribozymes that targeted PML/RARα for repression (26). RA treatment augmented expression of UBE1L, a retinoid target that repressed PML/RARα protein (8, 9). This also increased ISG15 expression in APL cells (7–9). These proteins repressed PML/RARα expression through a mechanism distinct from that of the ubiquitin–proteasome pathway (7–9, 27, 28).

This study explored whether RA regulated UBP43 expression. The kinetics of augmented UBP43 expression in retinoid sensitive versus resistant APL cells were related to UBE1L and ISG15 expression profiles. Anti-UBP43 antisera were derived from that of the ubiquitin–proteasome pathway (7–9, 27, 28).

Expression plasmids and transient transfection

The pcDNA4-UBP43, pSG5-UBE1L, His6-tagged pcDNA3-ISG15, pCMV-hemagglutinin (HA)-PML/RARα, pCMV-HA-PML, and pCMV-HA-RARα expression vectors were previously described (7–9). The full-length coding region of human UBP43 was cloned into the pcDNA3-IRES-ZsGreen1 vector (Clontech, Mountain View, CA) at BamH1 and Not1 restriction endonuclease sites to engineer the pRetroX-IRES-ZsGreen1-UBP43 retrovirus. The insertless retrovirus served as a control. The enhanced green fluorescent protein (EGFP) expression plasmid (EGFP-N2; Clontech), short hairpin RNA (shRNA)–UBP43 retroviruses (Open Biosystems, Huntsville, AL), and an insertless control vector (Open Biosystems) were purchased.

Materials and Methods

Cell culture

RA-sensitive NB4-S1 and RA-resistant NB4-R1 APL cell lines (7) were cultured in Advanced RPMI 1640 (Invitrogen, Carlsbad, CA) media with 2% fetal bovine serum (FBS; Gemini, Calabasas, CA), 4 mM L-glutamine (Invitrogen), 100 units/ml of penicillin (Invitrogen), and 100 μg/ml of streptomycin (Invitrogen) (8, 9). BEAS-2B–immortalized human bronchial epithelial cells were cultured in serum-free LHC-9 media (Biofluids, Akron, OH) (7, 8). COS-7 cells were cultured in Advanced DMEM (Invitrogen) media with 10% of FBS, 4 mmol/L of L-glutamine, 100 units/ml of penicillin, and 100 μg/ml of streptomycin. Cells were incubated at 37°C in a humidified incubator with 5% CO2.

Real-time RT-PCR assays

Total cellular RNA was isolated using Trizol Reagent (Invitrogen) and cDNA synthesis was performed using the High-Capacity cDNA Transcription Kit (Applied Biosystems, Foster City, CA) and a Peltier Thermal Cycler (MJ Research, Waltham, MA). Real-time RT-PCR assays were performed with iTaq Fast SYBR Green Supermix with an ROX Kit (Bio-Rad, Hercules, CA) and the 7500 Fast Real-time PCR System (Applied Biosystems). Three independent replicate experiments were performed. Primers were as follows: human UBP43 forward primer, 5′-TGGGCTCCCTGAGGAACCC-3′ and reverse primer, 5′-CGATGTGTTGTAACCAACCGGA-3′; UBE1L forward primer, 5′-CTACGAGCCGACTTCAAGCTT-3′ and reverse primer, 5′-TACACGAGGTTAGGAGGACAT-3′; ISG15 forward primer, 5′-AAGTGACGGAGGACTCTGA-3′ and reverse primer, 5′-CACCTTTCTTAAAGGCTGTCCTACAG-3′; GAPDH forward primer, 5′-AGTCTGGTGTGAACGGATTTG-3′ and reverse primer, 5′-TGTAGACCATTAGTATTGAGGCTA-3′.

Generation of stable UBP43-expressing APL transfectants

The pRetroX-IRES-ZsGreen1-UBP43 retroviral vector and an insertless control retrovirus were independently transfected into the RetroPack PT67 Packaging Cell Line (Clontech) using FuGENE 6 (Roche, Indianapolis, IN). Viral supernatants from transfectants were used to transduce NB4-R1 or NB4-S1 cells with 4 μg/ml of polybrene (Sigma, Milwaukee, WI). GFP-positive cells were harvested 48 hours later using a FACStar Plus cytometer (Becton Dickinson, San Jose, CA). This was repeated a week later to enrich for transductants, as done earlier (7). Doubly selected cells were studied. Three independent experiments were conducted with each study performed in triplicate.

The shRNA retrovirus selected for knockdown of UBP43 was isolated from PT67 cells and used to transduce independently NB4-S1 and NB4-R1 cells. Stable transductants...
were selected after 14 days of puromycin (2 μg/mL; Sigma) treatment. Several candidate shRNAs were transduced into NB4 cells and the one that most prominently knockeddown UBP43 was chosen for study.

**Generation of anti-UBP43 antisera**

Two rabbit polyclonal antibodies were derived (Covance, Denver, PA) against human UBP43 protein using 1 peptide nearer to the amino terminus (FDVDSKPLKTLEDALHC, anti-UBP43-1) than the other (CGKKTTRGKVKLTHLQ, anti-UBP43-2). Antibody specificities were confirmed by immunoblot analyses of COS-7-transfected cells with the pcDNA4-UBP43 construct versus controls. Preimmune antisera were used as additional controls.

**Immunoblot analyses**

APL and other cells were lysed with ice-cold radioimmuno-precipitation (RIPA) buffer using optimized methods (8, 9, 30). Lysates were size-fractionated by SDS-PAGE assays before transfer to nitrocellulose membranes (Whatman, Piscataway, NJ). Primary antibodies for immunoblot analyses were a rabbit polyclonal antibody that recognized PML/RARα (Abcam Inc., Cambridge, MA), a murine monoclonal antibody that recognized HA-tagged proteins (Babco, Richmond, CA) and a goat polyclonal antibody that recognized actin (Santa Cruz, Santa Cruz, CA). Anti-mouse and anti-rabbit antisera were purchased from Amersham (Piscataway, NJ) and anti-goat antiserum from Santa Cruz. These were used as respective secondary antibodies. Quantifications of signals were scored as before (7–9). To assess PML/RARα protein stability after UBP43 transfection, cells were treated with or without cycloheximide (CHX; 40 μg/mL; Sigma) for indicated time periods.

**Measurement of UBP43 activity**

UBP43 enzymatic activity in APL cells was assayed using established methods (31). Briefly, NB4-S1 cells were lysed in RIPA buffer and protein supernatants were incubated with or without HA-ISG15-vinylmethyl ester (HA-ISG15-VME, Boston Biochem Inc, Cambridge, MA) at 37°C for 60 minutes before incubation with protein G agarose beads (Pierce, Rockford, IL) and an anti-HA antibody (Santa Cruz) for at least 2 hours at 4°C to precipitate complexes. The HA-ISG15-VME probe forms an irreversible covalent bond with active deubiquitinas. Immunoblot analyses were independently performed using an anti-HA (Rockland, Gilbertsville, PA) or an anti-UBP43 antibody (anti-UBP43-1 or anti-UBP43-2).

**Proliferation and apoptosis assays**

The day before proliferation assays were conducted, the desired cells (1 × 10^5 cells/mL) were plated onto individual 6-well tissue culture plates. Three independent wells were seeded in each experiment with triplicate independent replicate experiments performed. Proliferation was measured using the CellTiter-Glo Assay Kit (Promega, Madison, WI) and established methods (29). Apoptosis was measured by Annexin V–FITC positivity by flow cytometry using the Annexin V Assay Kit (AbD Serotec, Raleigh, NC). Apoptosis within engineered APL cell lines was assayed with the Caspase-Glo 3/7 Assay Kit (Promega).

**Expression studies in transgenic APL mice**

Murine transgenic APL studies used previously optimized methods (32). The experiments were performed after review and approval by Dartmouth’s Institutional Animal Care and Use Committee (IACUC). Briefly, 4 female FVB mice (7-weeks old) were tail vein injected with 2 × 10^5 transgenic APL donor cells for each time point. Two of these mice were treated with RA and 2 were treated with dimethyl sulfoxide (DMSO) as a vehicle control. Twenty days after these injections, RA (2 mg) was intraperitoneally injected into each of the 2 mice and the same DMSO volume was administered to each control mouse. Clinical APL was evident 20 days after donor APL cell injections (32). RA-treated and control mice were independently sacrificed at indicated time points using IACUC-approved procedures. APL cells were harvested from spleens, as in prior work (32). Total RNA was isolated as before (7–9) for real-time RT-PCR assays. Findings from all mice treated in each respective arm were pooled for analyses.

**UBP43 expression in human APL cells**

Fresh APL cells were harvested as a part of an Institutional Review Board–approved protocol using previously optimized methods (32). APL cells were cultured in the presence of RA or vehicle (DMSO). RNA was harvested 24 hours after RA (1 μmol/L) or vehicle treatments. Differentiation response was scored by the percentage of nitrotetrazolium blue (NBT)-stained cells after 5 days of RA (100 nm) or vehicle treatments. Real-time RT-PCR assays for UBE1L, ISG15, UBP43, and GAPDH were each performed after 24 hours of RA treatment and results were compared with vehicle controls.

**Statistical analyses**

Two-tailed t tests were used. Results appear as mean ± SD. Statistical significance is noted in the text and figures as well as with the following symbols: *P* < 0.01 (*) and **P** < 0.005 (**).
consistent with an indirect RA-treatment effect on UBP43 expression in APL cells. This was supported by bioinformatic analysis of the UBP43 promoter. This did not reveal the presence of RA-responsive elements in the UBP43 promoter and UBP43 reporter activity in transfected BEAS-2B cells was not appreciably affected by RA treatment (data not shown).

UBP43 protein expression in APL cells

Different rabbit polyclonal antibodies recognizing UBP43 protein were derived (see Materials and Methods) to examine RA-treatment effects on UBP43 protein expression in APL cells. To confirm specificity of the 2 anti-UBP43 antibodies, COS-7 cells that did not basally express detectable UBP43 protein were transfected with a human UBP43 or an insertless control vector. As expected, COS-7 UBP43 transfectants expressed UBP43 protein identified by either anti-UBP43-1 or anti-UBP43-2 antibodies, but cells transfected with an insertless vector did not express this protein (Fig. 1B and C). In each case, preimmune serum was used as a negative control (Fig. 1B and C).

UBP43 is reported as the protease specific for ISG15 (13, 34). To confirm that the expected complex between ISG15 and UBP43 was formed in APL cells, NB4-S1 cell lysates were immunoprecipitated with an anti-HA antibody, before immunoblotting independently with an anti-HA or the anti-UBP43-1 antibody. UBP43 conjugated with ISG15 in these APL cells, as confirmed by an anti-HA or the anti-UBP43-1 antibody (Fig. 2A, two left panels). HA-tagged ISG15 is identified (hatched arrow, left panel) along with other possibly nonspecific species in Figure 2A (left and middle panels). UBP43 is expressed and active in these cells. Figure 2A (right panel) shows that UBP43 can remove ISG15 from PML/RARα protein.

Figure 1. All-trans-retinoic acid (RA) regulation of UBE1L, ISG15, and UBP43 mRNA expression in RA-sensitive versus RA-resistant acute promyelocytic leukemia (APL) cells. A, RA-sensitive NB4-S1 cells and RA-resistant NB4-R1 APL cells were each cultured with RA (1 μmol/L) or with vehicle for the indicated times in hours (h). UBE1L, ISG15, UBP43, and GAPDH mRNAs were each assessed by real-time RT-PCR assays. Similar results were obtained from 3 independent experiments. A representative result is shown. RA treatment induced UBE1L and ISG15 before UBP43 expression in NB4-S1 cells, but these species were not induced in NB4-R1 APL cells. B and C, immunogenic peptides generated the indicated anti-UBP43 polyclonal antibodies (see Materials and Methods). UBP43 protein was detected in COS-7 cells transfected with pcDNA4-UBP43 (+), but not with an insertless control pcDNA4 vector (−). The 43-kDa UBP43 protein was detected using these respective antibodies. This protein was not detected when preimmune sera for each antibody was probed to each respective filter. Molecular weight size markers are displayed.
Next, RA regulation of UBP43 protein was examined. Induction of UBP43 protein followed RA treatment of RA-sensitive NB4-S1 cells, but not of RA-resistant NB4-R1 cells (Fig. 2B and C). Quantifications of signals appear below these immunoblots. RA treatment augmented UBE1L and ISG15 protein expression and destabilized PML/RARα protein (8, 9). UBP43 mRNA induction followed that of UBE1L and ISG15 mRNAs raising the possibility that UBP43 directly affected PML/RARα protein stability. Experiments were conducted to examine this.

**UBP43-affected PML/RARα stability**

UBE1L repressed PML/RARα protein by targeting the PML, but not the RARα domain of PML/RARα (9); UBP43 antagonized this UBE1L effect (9). UBP43 effects on stabilities of different PML/RARα domains were uncovered by transient cotransfection experiments using constructs (9) expressing full-length PML/RARα, or respective PML or RARα domains of PML/RARα. Immunoblot analyses revealed that UBP43 cotransfection in BEAS-2B cells enhanced expression of both full-length PML/RARα (Fig. 3A, construct 1) and the PML domain of PML/RARα (Fig. 3A, construct 2), but no effects were observed on the expressed RARα domain of PML/RARα (Fig. 3A, construct 3). Quantification for each respective signal is presented in the corresponding right panels of Figure 3A. Similar transfection efficiencies were achieved in each arm of the experiments as confirmed by EGFP expression vector cotransfection and immunoblot experiments, as displayed in this figure. Engineered UBP43 overexpression did not appreciably affect the proportion of EGFP-expressing transfected cells (data not shown and Fig. 3A).

To study further UBP43 effects on PML/RARα protein stability, UBP43 was cotransfected with an HA-tagged
UBP43 and apoptosis

Prior work found that UBE1L triggered PML/RARα degradation and apoptosis in APL cells (7–9). Whether UBP43 affected apoptosis in APL cells by targeting PML/RARα protein was studied. To ascertain effects of UBP43 on PML/RARα expression, 2 different siRNAs targeting UBP43 and a RISC-free control siRNA were independently transfected into NB4-S1 cells (Fig. 3C, left panel). Knockdown of UBP43 by each of these UBP43-targeting siRNAs significantly decreased UBP43 and PML/RARα immunoblot expression versus controls in APL cells. Actin expression was unaffected (Fig. 3C). Compared with RISC-free siRNA controls, knockdown of UBP43 by each siRNA targeting UBP43 significantly augmented apoptosis, as confirmed by Annexin V and propidium iodide staining and fluorescence-activated cell sorting analysis (Fig. 3D). Compared with RISC-free control cells, UBP43 knockdown in NB4-S1 cells augmented apoptosis at day 1 and this increased over the 3 days of this study. A decline in PML/RARα protein accompanied this (Fig. 3C).

To confirm and extend these transient UBP43 knockdown findings, stable retroviral shRNA-mediated repression of UBP43 was achieved. The consequences of this on PML/RARα expression and on apoptosis were studied in NB4 transductants. Stable knockdown of UBP43 was engineered by retroviral transductions and puromycin selection of the desired shRNA independently expressed in NB4-R1 and NB4-S1 cells. Figure 4A established that shRNA-mediated
UBP43 knockdown reduced endogenous PML/RARα expression in both transduced APL cell lines (relative to insertless vector controls). Stable UBP43 knockdown in NB4-R1 and NB4-S1 cells significantly increased apoptosis in both the cells (Fig. 4B). RA treatment of UBP43 knockdown NB4-S1 cells did significantly promote apoptosis but did not affect differentiation response (Supplementary Fig. S1). Figure 4B showed that compared with these respective control transfectants, UBP43 knockdown in these APL cells produced significant (**, P < 0.005) apoptosis.

UBP43 overexpression was independently achieved in NB4-S1 and NB4-R1 cells, as shown in Figure 5. Unlike UBP43 knockdown, retroviral-mediated UBP43 overexpression augmented PML/RARα expression in both APL cell lines (Fig. 5A) and reduced apoptosis (Fig. 5B) relative to insertless vector controls.

**UBP43-regulated APL cell growth**

Because UBP43 knockdown promoted apoptosis in APL cells by targeting PML/RARα for repression, effects of UBP43 knockdown on growth were studied in NB4 cells with engineered loss or gain of UBP43 expression. CellTiter-Glo assays confirmed that UBP43 knockdown conferred a marked repression of NB4-S1 and NB4-R1 APL cell growth (Fig. 4C). In contrast, engineered UBP43 overexpression significantly (**, P < 0.005) promoted growth as compared with insertless vector controls for both APL cell lines (Fig. 5C).

**RA treatment of APL mice**

To determine whether RA induced UBP43 expression in vivo, a murine transgenic transplantable APL model was studied (35). Clinical evidence of APL occurred in recipients 20 days after transgenic APL cell injections into FVB mice. Mice were then sacrificed and RNA was isolated from harvested spleens (see Materials and Methods). UBE1L, ISG15, and UBP43 mRNA expression profiles were each significantly augmented after RA treatment versus vehicle control-treated APL mice (Fig. 6A). These findings extended results from cultured APL cells to the setting of APL in mice.
RA treatment of APL cells from patients

Whether RA increased UBE1L, ISG15, and UBP43 mRNA expression profiles in cultures of leukemic cells was studied in APL cells harvested directly from patients. APL cells from 2 different RA-responsive cases augmented UBE1L, ISG15, and UBP43 mRNA expression after 24 hours of RA treatment relative to controls (Fig. 6B). No significant change in UBE1L expression was observed, but when the ISG15 and UBP43 results after RA treatment were pooled, significant changes were observed ($P = 0.0024, n = 3$). RA treatment also caused differentiation to occur in RA-sensitive cases, as shown by increased NBT-positive APL cells (Fig. 6B). Cells from a representative RA-resistant APL case with an inactivating PML/RAR$\alpha$ ligand-binding domain mutation similar to that in NB4-R1 cells (36, 37) were examined. Deregulated UBE1L, ISG15, and UBP43 expression and minimal NBT augmentation were observed, despite RA treatment of these APL cells (Fig. 6B).

Discussion

This study builds on prior work that revealed retinoid treatment of APL cells augmented UBE1L and ISG15 expression and ISG15ylation (8, 9) by showing that the deconjugase, UBP43, is also regulated by RA treatment of APL cells. RA induction of UBP43 mRNA did not increase until 48 hours (Fig. 1A). That retinoid effects on UBP43 were indirect was consistent with bioinformatic analysis and UBP43 reporter assay results. RA-mediated induction of UBP43 occurred in RA-sensitive but not in RA-resistant APL cells (Figs. 1 and 2). RA treatment also augmented UBE1L and ISG15 mRNA expression in RA-sensitive but not in RA-resistant APL cells. Increased UBE1L and ISG15 expression accompanied RA treatment, but occurred earlier than did UBP43 induction. This indicated that a negative regulatory loop likely exists to limit ISG15ylation (8) via induction of
UBP43. Assays displayed in Figure 2A showed that UBP43 was expressed and functionally active in APL cells. PML/RARα expression is diagnostic for APL (2, 3). Leukemic cell growth and differentiation are linked to PML/RARα expression (4, 5). Loss of PML/RARα markedly affected APL cell growth. Prior work revealed that ribozyme-mediated repression of PML/RARα was antileukemic at least partly by triggering apoptosis of RA-sensitive and RA-resistant APL cells (26, 37). RA and arsenic trioxide also individually triggered PML/RARα degradation and conferred differentiation or apoptosis, respectively, as reviewed (38). RA treatment caused PML/RARα degradation through caspase- and proteasome-dependent mechanisms (9, 28, 39). RA engaged caspase-3, which targeted PML/RARα for repression (39). Likewise, UBE1L was induced by RA treatment, and this repressed PML/RARα expression and promoted apoptosis (7).

IFN treatment augmented UBE1L, ISG15, and UBP43 expression (13, 15–17). Retinoids can crosstalk with UBE1L and ISG15 protein expression (7–9, 33). This was previously implicated in regulating PML/RARα stability and apoptosis (7, 9). That UBP43 is an antineoplastic target was suggested by previous retinoid work (7, 9).

The present study extended that work by showing UBP43 regulated PML/RARα protein stability. Prior findings indicated that PML/RARα can undergo ISG15ylation and target the PML domain for repression, but on the contrary, RA affected PML/RARα stability through its RARα domain (9). These findings reveal that 2 distinct degradation pathways are activated by RA treatment. In the current study, transfection experiments

Figure 6. RA treatment of a murine transgenic transplantable APL model and of APL cells harvested directly from patients. A, UBE1L, ISG15, and UBP43 mRNA expression profiles were each studied in RA-treated versus vehicle control-treated APL mice (see Materials and Methods). After RA treatment for the indicated hours (h), UBE1L, ISG15, and UBP43 mRNAs were each increased in the isolated spleens. B, RA treatment induced UBE1L, ISG15, and UBP43 mRNA expression in cultured human APL cells from 2 representative RA-responsive cases, but not appreciably in a representative RA-resistant APL case. Expression profiles were studied after RA treatment or no treatment and differentiation response was assessed by nitrotetrazolium blue (NBT) staining as described in the Materials and Methods. NBT-positive cells appeared after RA treatment of RA-responsive but minimally in RA-resistant APL cells from these cases. Significant changes are indicated (**, *P* < 0.005).
found that UBP43 also has domain-specific PML/RARα effects that targeted for repression the PML but not RARα domain, in accord with prior work that studied UBE1L effects in APL cells (9). Future work should determine which residue(s) in the PML domain of PML/RARα undergo ISG15 modification.

This study directly linked UBP43 to PML/RARα stabilization by showing that increased PML/RARα protein stability followed UBP43 transfection, despite CHX treatment (Fig. 3B). As expected, knockdown of UBP43 destabilized PML/RARα protein and promoted apoptosis in APL cells (Figs. 4 and 5). Yet, differentiation was not apparently affected as was the case following ribozyme-dependent or arsenic-mediated PML/RARα degradation (25, 26, 37). In contrast, UBP43 overexpression stabilized PML/RARα protein and promoted APL cell growth (Figs. 4 and 5), indicating that PML/RARα exerts antiapoptotic effects in APL.

Prior work directly implicated PML in regulation of apoptosis and proliferation (40). PML effects on cell growth might be from its ability to promote apoptosis through intrinsic or extrinsic pathways (41). PML affects apoptosis through different mechanisms, either by serving as a transcriptional modification and activation platform for the p53 tumor suppressor, or by pathways (41). PML affects apoptosis through different pathways (41). PML affects apoptosis through different mechanisms, either by serving as a transcriptional modification and activation platform for the p53 tumor suppressor, or by regulating expression and localization of apoptotic regulators, as reviewed (40–42). Prior work found that arsenic treatment increased PML assembly into PML nuclear bodies, important for PML regulation of apoptosis. This assembly depends on posttranslational modification of PML with small ubiquitin-like modifier 1 (SUMO-1) (40–42). SUMO is related to ISG15, but SUMOylation engages distinct effects, as reviewed (40–42).

The hypothesis that UBP43 is an antineoplastic target is consistent with recent work reported with the deubiquitinase USP9X, which promoted cancer cell survival by regulating stability of a prosurvival BCL2 family member (43). Analogous to that study, it was found here that knockdown of another deconjugase, UBP43, destabilized PML/RARα protein and triggered apoptosis whereas gain of UBP43 expression opposed these effects. Notably, UBP43 was found to be active in APL cells (Fig. 2A). Findings from mice and patients with APL revealed that UBP43 is expressed in APL cells and regulated by RA treatment (Fig. 6). Given this, pharmacologic inhibition of UBP43 would likely affect not only APL biology, but also APL therapy.

In summary, this study identified UBP43 as an antineoplastic target in APL. UBP43 directly affected PML/RARα stability and regulated APL cell growth. Knockdown of UBP43 repressed PML/RARα and this, in turn, reduced APL cell growth by promoting apoptosis. Pharmacologic targeting of the UBE1L-ISP15-UBP43 pathway, especially through inhibition of UBP43, is an appealing therapeutic approach to consider in APL and other malignancies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest exist.

Acknowledgments

The authors thank Dr. Sutisak Kitareewan for his helpful consultation.

Grant Support

This work was supported by National Institutes of Health (NIH) and National Cancer Institute (NCI) grants R01-CA087546 (E. Dmitrovsky), R01-CA111422 (E. Dmitrovsky), R01-CA062275 (E. Dmitrovsky), R01-CA56771 (R. Gallagher), by a Samuel Waxman Cancer Research Foundation Award (E. Dmitrovsky), and by an American Cancer Society Institutional grant (S. Freemantle). E. Dmitrovsky is an American Cancer Society Clinical Research Professor supported by a generous gift from the F.M. Kirby Foundation.

Received 03/29/2010; revised 09/01/2010; accepted 09/20/2010; published OnlineFirst 10/08/2010.

References


Blockade of the Ubiquitin Protease UBP43 Destabilizes Transcription Factor PML/RARα and Inhibits the Growth of Acute Promyelocytic Leukemia

Yongli Guo, Andrey V. Dolinko, Fadzai Chinyengetere, et al.

Cancer Res Published OnlineFirst October 8, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1100

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/08/0008-5472.CAN-10-1100.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.